AKT1 and breast carcinoma: We have established that, at nanomolar doses, VD3-GNP treatment (24 h) mitigates breast cancer (MDA-MB-231 and MCF-7) cells’ aggression, by reducing invasion, migration, and adhesion, along with downregulating important proteins in cell signaling pathways, e.g., PI3K/mTOR/AKT, including the transcription factor ETV7 and Hippo cascades (quantitated using Western blots).